CureMeAbroad Raises $1.1 Million in Pre-Seed Funding to Expand Medical Tourism Platform

CureMeAbroad, a healthcare platform connecting patients with accredited hospitals abroad, has raised $1.1 million in a pre-seed funding round led by SteerX Ventures. The startup plans to use the funds to expand its network, enter new markets, and strengthen its AI-powered verification tools.

Funding Details and Plans

CureMeAbroad, a Pune-based healthcare platform, has raised $1.1 million in a pre-seed funding round led by SteerX Ventures. Existing investor AIRA also participated in the round, according to Entrackr. This follows an earlier $600,000 raise in April 2026 from individual and institutional investors, including Roman Saini, Himanshu Ratnoo, and AIRA.

The startup plans to allocate the fresh capital toward expanding its accredited hospital network, entering new patient source markets, and strengthening its AI-powered technology. Additional funds will be used to build out operations and technology teams, with a focus on non-elective specialties such as orthopaedics and oncology.

Platform Traction and Goals

CureMeAbroad operates as a healthcare-tech platform that helps international patients discover, compare, and verify hospitals, obtain treatment estimates, and book care across multiple destinations. The platform currently attracts over 22,500 visitors per month and spans a network of more than 400 accredited hospitals across six countries.

Key patient source markets include the US, UK, Australia, and Canada. CureMeAbroad has also received Medical Travel Facilitator Certification from Global Healthcare Accreditation, a trust signal for patients and partners.

The startup’s current run rate stands at $4.8 million, and it is targeting $100 million in annual patient treatment bookings by FY2028.

Founders and Market Context

CureMeAbroad was founded in June 2025 by Aditya Oza and Mikhail Bohra. The medical tourism sector is crowded, with competitors like Bookimed, PlacidWay, The Medical Tourism Company, Medical Departures, and India-based Vaidam Health all vying for market share.

The startup’s focus on AI-powered verification and expansion into non-elective treatments could help differentiate it from competitors, many of which rely on more traditional models of patient-hospital matching.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

CureMeAbroad’s pre-seed funding round reflects a growing interest in digitizing and scaling medical tourism. For founders, this deal underscores the importance of trust signals—like accreditation and verified hospital networks—in attracting both investors and patients. The focus on non-elective specialties, such as orthopaedics and oncology, also suggests a shift beyond cosmetic or elective procedures, which have dominated the medical tourism space.

For operators, the challenge lies in balancing rapid expansion with quality control. AI-powered tools can streamline patient matching and verification, but scaling a network of accredited hospitals requires strong local partnerships. The $100 million target for FY2028 is ambitious, but if achieved, it could position CureMeAbroad as a serious contender in a fragmented market. Competitors like Vaidam Health and Bookimed are already established, so differentiation—whether through technology, pricing, or specialty focus—will be key.

Investors may see this as a bet on the globalization of healthcare, particularly as cost disparities and wait times drive patients to seek treatment abroad. However, regulatory hurdles and cultural barriers could slow adoption, making execution the biggest risk.

Key takeaways

• Medical tourism startups are attracting early-stage funding to scale operations and technology.
• AI-powered platforms like CureMeAbroad are leveraging accreditation and verification to build trust in global healthcare markets.
• Expansion into non-elective specialties could diversify revenue streams for medical tourism platforms.
• Early traction, such as CureMeAbroad’s $4.8 million run rate, is critical for securing pre-seed funding in competitive sectors.

FAQ

What is CureMeAbroad?

CureMeAbroad is a Pune-based healthcare platform that connects international patients with vetted and accredited hospitals abroad. It helps users discover, compare, and book treatments across multiple countries.

How will CureMeAbroad use the $1.1 million funding?

The funds will be used to expand its accredited hospital network, enter new markets like the US and UK, enhance its AI-powered technology, and build operations and technology teams. The startup also plans to focus on non-elective specialties such as orthopaedics and oncology.

Who are CureMeAbroad’s competitors?

CureMeAbroad competes with platforms like Bookimed, PlacidWay, The Medical Tourism Company, Medical Departures, and Vaidam Health.

What is CureMeAbroad’s target for FY2028?

The startup is targeting $100 million in annual patient treatment bookings by FY2028.

Who invested in CureMeAbroad’s pre-seed round?

The $1.1 million pre-seed round was led by SteerX Ventures, with participation from existing investor AIRA. Individual investors like Roman Saini, Himanshu Ratnoo, and Kunal Gupta also contributed.

Related on Lazyfounder

• More startup news